- Home
- RBCAA vs BCYC Comparison
RBCAA vs BCYC Comparison
Compare RBCAA & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBCAA
- BCYC
- Stock Information
- Founded
- RBCAA 1974
- BCYC 2009
- Country
- RBCAA United States
- BCYC United Kingdom
- Employees
- RBCAA N/A
- BCYC N/A
- Industry
- RBCAA Major Banks
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- RBCAA Finance
- BCYC Health Care
- Exchange
- RBCAA Nasdaq
- BCYC Nasdaq
- Market Cap
- RBCAA 1.3B
- BCYC 1.9B
- IPO Year
- RBCAA 1998
- BCYC 2019
- Fundamental
- Price
- RBCAA $67.75
- BCYC $26.74
- Analyst Decision
- RBCAA
- BCYC Buy
- Analyst Count
- RBCAA 0
- BCYC 9
- Target Price
- RBCAA N/A
- BCYC $42.00
- AVG Volume (30 Days)
- RBCAA 17.8K
- BCYC 461.6K
- Earning Date
- RBCAA 11-01-2024
- BCYC 10-31-2024
- Dividend Yield
- RBCAA 2.41%
- BCYC N/A
- EPS Growth
- RBCAA 12.30
- BCYC N/A
- EPS
- RBCAA 4.92
- BCYC N/A
- Revenue
- RBCAA $317,422,000.00
- BCYC $39,574,000.00
- Revenue This Year
- RBCAA N/A
- BCYC $58.69
- Revenue Next Year
- RBCAA $2.56
- BCYC N/A
- P/E Ratio
- RBCAA $13.66
- BCYC N/A
- Revenue Growth
- RBCAA 3.94
- BCYC 75.74
- 52 Week Low
- RBCAA $42.51
- BCYC $12.54
- 52 Week High
- RBCAA $69.00
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- RBCAA 64.98
- BCYC 63.17
- Support Level
- RBCAA $62.14
- BCYC $22.82
- Resistance Level
- RBCAA $64.39
- BCYC $28.67
- Average True Range (ATR)
- RBCAA 1.32
- BCYC 1.35
- MACD
- RBCAA 0.38
- BCYC 0.39
- Stochastic Oscillator
- RBCAA 93.71
- BCYC 72.11
About RBCAA Republic Bancorp Inc.
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through six reportable segments. It has traditional banking which generates the majority of revenue, warehouse, mortgage banking, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.